Cannabis Strategic Ventures, Inc. Signs Binding Letter of Intent with Scopien Technologies Inc.
All legacy Series C Preferred Stock has been cancelled following the company’s court-supervised restoration.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cannabis Strategic Ventures (OTC: NUGS) signed a binding letter of intent to combine with Scopien Technologies, an Ontario AI platform company. Scopien would acquire voting control through a transfer of NUGS’s Series B Super Voting Preferred Stock and contribute its operating business. The parties intend to complete the change of control by November 30, 2026.
NUGS terminated its non-binding Adport acquisition letter of intent; no definitive agreements were signed. NUGS plans audits and an SEC registration filing within six months after the control change, targeting fully reporting status and a Nasdaq or NYSE listing. Reported liabilities were approximately $491,000 at September 30, 2026, versus more than $14.6 million in legacy liabilities when a custodian was appointed in July 2025.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Binding Scopien agreement provides for an operating-business contribution, with the control change targeted by November 30, 2026.
- Major pointReported liabilities were approximately $491,000 at September 30, 2026, versus legacy liabilities exceeding $14.6 million in July 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.PCAOB audits and SEC registration filing are planned within six months following the change of control.
- Minor pointAll legacy Series C Preferred Stock has been cancelled.
- Minor point. Forward-looking: it has not happened yet and may not happen.Fully reporting status and a Nasdaq or NYSE listing are company goals.
Negative
- Minor pointAdport acquisition letter of intent terminated; no definitive agreements were entered into.
- Minor point. Forward-looking: it has not happened yet and may not happen.Planned name and trading-symbol changes remain subject to FINRA processing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Following a court-supervised restoration, NUGS plans to combine with Scopien, a sovereign AI platform
LOS ANGELES, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cannabis Strategic Ventures, Inc. (OTC: NUGS) (“NUGS” or the “Company”) today announced that it signed a binding letter of intent (the “LOI”) with Scopien Technologies Inc. (“Scopien”), an Ontario corporation. Under the LOI, Scopien would acquire voting control of NUGS through the transfer of the Company’s Series B Super Voting Preferred Stock and contribute its operating business to the Company. The parties intend to complete the change of control by November 30, 2026.
Termination of Adport Letter of Intent
The Company also announced that it has terminated the non-binding letter of intent with Adport Inc. announced on September 10, 2026, under which the Company had proposed to acquire substantially all of Adport’s intellectual property and operating assets. No definitive agreements were entered into with Adport.
About the Scopien Platform
Scopien connects a company’s systems, including CRM, ERP, HR, payroll and helpdesk, into one operating platform and puts AI agents to work across it. Each customer runs its own instance in Scopien’s cloud, its own cloud or on-premises, so data stays inside its walls. Scopien serves mid-market companies, enterprises and government, and plans to expand its sales and partner channels, product modules and engineering program.
What Comes Next
When the change of control closes, Scopien would appoint NUGS’s officers and directors. The Company intends to change its name and trading symbol to reflect the Scopien business, subject to FINRA processing, and to complete PCAOB audits and file a registration statement with the SEC within six months following the change of control, with the goal of becoming a fully reporting company and pursuing a Nasdaq or NYSE listing.
“We rebuilt this company through the courts so shareholders would have something real to build on,” said Richard C. Hawkins, Chief Executive Officer of NUGS. “Scopien is the kind of company we hoped to find.”
“Every business should work as one,” said Zameer Mulla, Chief Executive Officer of Scopien. “Being a public company holds us to the standard of transparency our customers expect. Our first priority is completing the audit and the registration statement.”
Court Custodianship
In July 2025, the Eighth Judicial District Court of Nevada, Clark County, appointed a custodian for the Company, which at the time had no operations and carried more than
About Scopien Technologies Inc.
Scopien Technologies Inc., based in Oakville, Ontario, builds sovereign AI that makes every business work as one. For more information, visit www.scopien.com.
About Cannabis Strategic Ventures, Inc.
Cannabis Strategic Ventures, Inc. is a Nevada corporation quoted on OTC Markets under the symbol “NUGS.” Following a court-supervised custodianship completed in April 2026, the Company is pursuing business combinations with operating businesses that have growth potential.
Investor Contact
info@cannabisstrategic.ventures | +1 480-788-7420
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the proposed change of control, the contribution of Scopien’s business, the audit and registration statement, and potential exchange listing. These statements are subject to significant risks and uncertainties, including: that definitive agreements may not be executed or the LOI may be terminated; that the audit and registration statement may not be completed as contemplated; that Scopien’s business may not grow as anticipated; that additional funding may not be available; that securities remain subject to former-shell-company resale restrictions under Rule 144(i); that exchange listing standards may not be met; and that legacy indebtedness and future financing may substantially dilute common stockholders. The super-voting preferred stock would concentrate voting control in Scopien.
The safe harbor provided by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 is not available to the Company. The Company undertakes no obligation to update any forward-looking statement except as required by law. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Source: Cannabis Strategic Ventures, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms and timing of NUGS’s proposed Scopien combination?
Scopien would acquire voting control of NUGS through the transfer of its Series B Super Voting Preferred Stock and contribute its operating business. The parties signed a binding letter of intent and intend to complete the change of control by November 30, 2026.
Who would appoint NUGS’s leadership after the Scopien change of control?
Scopien would appoint NUGS’s officers and directors when the change of control closes.